Equities

Kymera Therapeutics Inc

KYMR:NMQ

Kymera Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)50.00
  • Today's Change-1.84 / -3.55%
  • Shares traded308.74k
  • 1 Year change+244.35%
  • Beta2.2173
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments375407442
Total Receivables, Net192.540.14
Total Inventory------
Prepaid expenses129.718.72
Other current assets, total------
Total current assets405419451
Property, plant & equipment, net1012221
Goodwill, net------
Intangibles, net------
Long term investments61152125
Note receivable - long term------
Other long term assets2.123.022.02
Total assets576603606
LIABILITIES
Accounts payable7.084.344.01
Accrued expenses353025
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.281.411.14
Other current liabilities, total423662
Total current liabilities867193
Total long term debt1.301.251.14
Total debt2.582.652.28
Deferred income tax------
Minority interest------
Other liabilities, total944053
Total liabilities181113146
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital926879689
Retained earnings (accumulated deficit)(531)(384)(229)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.55)(4.95)(0.66)
Total equity395490460
Total liabilities & shareholders' equity576603606
Total common shares outstanding565552
Treasury shares - common primary issue000.04
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.